A novel strategy to modify adenovirus tropism and enhance transgene delivery to activated vascular endothelial cells in vitro and in vivo.

To assess the possibilities of retargeting adenovirus to activated endothelial cells, we conjugated bifunctional polyethylene glycol (PEG) onto the adenoviral capsid to inhibit the interaction between viral knob and coxsackie-adenovirus receptor (CAR). Subsequently, we introduced an alphav integrin-specific RGD peptide or E-selectin-specific antibody to the other functional group of the PEG molecule for the retargeting of the adenovirus to activated endothelial cells. In vitro studies showed that this approach resulted in the elimination of transgene transfer into CAR-positive cells, while at the same time specific transgene transfer to activated endothelial cells was achieved. PEGylated, retargeted adenovirus showed longer persistence in the blood circulation with area under plasma concentration-time curve (AUC) values increasing 12-fold compared to unmodified virus. Anti-E-selectin antibody-PEG-adenovirus selectively homed to inflamed skin in mice with a delayed-type hypersensitivity (DTH) inflammation, resulting in local expression of the reporter transgene luciferase. This is the first study showing the benefits of PEGylation on adenovirus behavior upon systemic administration. The approach described here can form the basis for further development of adenoviral gene therapy vectors with improved pharmacokinetics and increased efficiency and specificity of therapeutic gene transfer into endothelial cells in disease.

[1]  R. Wood,et al.  SELECTIVE INTRACELLULAR DELIVERY OF DEXAMETHASONE INTO ACTIVATED ENDOTHELIAL CELLS USING AN E-SELECTIN-DIRECTED IMMUNOCONJUGATE , 2003, Pediatrics.

[2]  Grietje Molema,et al.  Delivery of pharmacologically active dexamethasone into activated endothelial cells by dexamethasone-anti-E-selectin immunoconjugate. , 2003, Biochemical pharmacology.

[3]  J. Proost,et al.  Targeting of RGD‐modified proteins to tumor vasculature: A pharmacokinetic and cellular distribution study , 2002, International journal of cancer.

[4]  N. Abraham,et al.  TNF-α-mediated cell death is attenuated by retrovirus delivery of human heme oxygenase-1 gene into human microvessel endothelial cells , 2002 .

[5]  J. Bergelson,et al.  Soluble coxsackievirus adenovirus receptor is a putative inhibitor of adenoviral gene transfer in the tumor milieu. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  E. Paleolog.  Angiogenesis in rheumatoid arthritis , 2002, Arthritis research.

[7]  R. Alemany,et al.  CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors , 2001, Gene Therapy.

[8]  D. Curiel,et al.  Combined transductional and transcriptional targeting improves the specificity of transgene expression in vivo , 2001, Nature Biotechnology.

[9]  James M. Wilson,et al.  “Stealth” Adenoviruses Blunt Cell-Mediated and Humoral Immune Responses against the Virus and Allow for Significant Gene Expression upon Readministration in the Lung , 2001, Journal of Virology.

[10]  D. Spencer,et al.  A strategy for antitumor vascular therapy by targeting the vascular endothelial growth factor: receptor complex. , 2001, Cancer research.

[11]  P. Carmeliet,et al.  Angiogenesis in cancer and other diseases , 2000, Nature.

[12]  U. Modlich,et al.  Increasing endothelial cell specific expression by the use of heterologous hypoxic and cytokine-inducible enhancers , 2000, Gene Therapy.

[13]  T. Veikkola,et al.  Regulation of angiogenesis via vascular endothelial growth factor receptors. , 2000, Cancer research.

[14]  H. Romanczuk,et al.  Modification of an adenoviral vector with biologically selected peptides: a novel strategy for gene delivery to cells of choice. , 1999, Human gene therapy.

[15]  Erkki Ruoslahti,et al.  Anti-cancer activity of targeted pro-apoptotic peptides , 1999, Nature Medicine.

[16]  J. Kamps,et al.  Selective transfer of a lipophilic prodrug of 5-fluorodeoxyuridine from immunoliposomes to colon cancer cells. , 1999, Biochimica et biophysica acta.

[17]  N. Chapman,et al.  Expression of the Coxsackievirus and Adenovirus Receptor in Cultured Human Umbilical Vein Endothelial Cells: Regulation in Response to Cell Density , 1999, Journal of Virology.

[18]  D. Curiel,et al.  Insertion of an RGD motif into the HI loop of adenovirus fiber protein alters the distribution of transgene expression of the systemically administered vector , 1999, Gene Therapy.

[19]  E. Hoffman,et al.  Polylysine modification of adenoviral fiber protein enhances muscle cell transduction. , 1999, Human gene therapy.

[20]  D. Vestweber,et al.  Molecular mechanisms that control leukocyte extravasation: the selectins and the chemokines. , 1999, Histochemistry and cell biology.

[21]  J. Bischoff,et al.  Noninflammatory expression of E-selectin is regulated by cell growth. , 1999, Blood.

[22]  R. Crystal,et al.  CAR-dependent and CAR-independent pathways of adenovirus vector-mediated gene transfer and expression in human fibroblasts. , 1999, The Journal of clinical investigation.

[23]  D. Brenner,et al.  NFkappaB prevents apoptosis and liver dysfunction during liver regeneration. , 1998, The Journal of clinical investigation.

[24]  D. Brough,et al.  Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins , 1997, Journal of virology.

[25]  J. Kolls,et al.  Liver-directed gene transfer in non-human primates. , 1997, Human gene therapy.

[26]  J. Bergelson,et al.  Isolation of a Common Receptor for Coxsackie B Viruses and Adenoviruses 2 and 5 , 1997, Science.

[27]  D. Brough,et al.  Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types , 1996, Nature Biotechnology.

[28]  D. Curiel,et al.  Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism , 1996, Journal of virology.

[29]  Hanns Lochmüller,et al.  The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants. , 1995, Gene therapy.

[30]  J Engel,et al.  Selective recognition of cyclic RGD peptides of NMR defined conformation by alpha IIb beta 3, alpha V beta 3, and alpha 5 beta 1 integrins. , 1994, The Journal of biological chemistry.

[31]  D. Cheresh,et al.  Requirement of vascular integrin alpha v beta 3 for angiogenesis. , 1994, Science.

[32]  G. Molema,et al.  In Vitro Cellular Handling and in Vivo Targeting of E-Selectin-Directed Immunoconjugates and Immunoliposomes Used for Drug Delivery to Inflamed Endothelium , 2004, Pharmaceutical Research.

[33]  S. Negrotto,et al.  [Angiogenesis in cancer]. , 2002, Medicina.

[34]  Grietje Molema,et al.  Preparation and functional evaluation of RGD-modified proteins as alpha(v)beta(3) integrin directed therapeutics. , 2002, Bioconjugate chemistry.

[35]  D. Brenner,et al.  Prevents Apoptosis and Liver Dysfunction during Liver Regeneration , 1998 .

[36]  Erkki Ruoslahti,et al.  αv Integrins as receptors for tumor targeting by circulating ligands , 1997, Nature Biotechnology.

[37]  G. Molema,et al.  Preparation and Functional Evaluation of RGD-Modified Proteins as r v â 3 Integrin Directed Therapeutics , 2022 .